Company registration number 07090581 (England and Wales)
PHARMEASY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PHARMEASY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
PHARMEASY LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
183,189
213,720
Tangible assets
4
131,582
138,846
314,771
352,566
Current assets
Stocks
55,140
65,640
Debtors
5
564,511
508,359
Cash at bank and in hand
522,105
388,277
1,141,756
962,276
Creditors: amounts falling due within one year
6
(733,101)
(595,769)
Net current assets
408,655
366,507
Total assets less current liabilities
723,426
719,073
Provisions for liabilities
(3,198)
-
0
Net assets
720,228
719,073
Capital and reserves
Called up share capital
4
4
Profit and loss reserves
720,224
719,069
Total equity
720,228
719,073

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 17 November 2025 and are signed on its behalf by:
Kamran Sarwar
Director
Company registration number 07090581 (England and Wales)
PHARMEASY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Pharmeasy Limited is a private company limited by shares incorporated in England and Wales. The registered office is 65 Woolmore Road, Erdington, Birmingham, B23 7EB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Intangible fixed assets - goodwill

Goodwill is being written off in equal annual instalments over its estimated economic life of 10 years.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property
2% on cost
Plant and equipment
18% on reducing balance
Computers
18% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

PHARMEASY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

1.8
Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
23
29
3
Intangible fixed assets
Goodwill
£
Cost
At 1 April 2024 and 31 March 2025
305,313
Amortisation and impairment
At 1 April 2024
91,593
Amortisation charged for the year
30,531
At 31 March 2025
122,124
Carrying amount
At 31 March 2025
183,189
At 31 March 2024
213,720
PHARMEASY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 4 -
4
Tangible fixed assets
Improvements to property
Plant and equipment
Computers
Total
£
£
£
£
Cost
At 1 April 2024 and 31 March 2025
114,000
63,064
3,123
180,187
Depreciation and impairment
At 1 April 2024
2,280
38,499
562
41,341
Depreciation charged in the year
2,280
4,422
562
7,264
At 31 March 2025
4,560
42,921
1,124
48,605
Carrying amount
At 31 March 2025
109,440
20,143
1,999
131,582
At 31 March 2024
111,720
24,565
2,561
138,846
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
480,806
424,901
Other debtors
83,705
83,458
564,511
508,359
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
416,689
331,865
Corporation tax
45,408
35,303
Other taxation and social security
150
3,413
Other creditors
270,854
225,188
733,101
595,769
PHARMEASY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
7
Directors' transactions

The following advances and credits to a director subsisted during the years ended 31 March 202 5 and 31 March 202 4:

Description
% Rate
Opening balance
Amounts repaid
Closing balance
£
£
£
Kamran Sarwar - Loan
-
12,977
(12,977)
-
12,977
(12,977)
-

The loan was unsecured, interest free and repaid in full.

8
Ultimate Controlling Party

The controlling party is Kamran Sarwar.

9
Related Party Disclosures

As at 31 March 202 5 the following balances, included in other debtors due within one year, w as due from a

related company:

Rhodium Pharma Ltd: £4,500

The above balance is repayable on demand.

2025-03-31 2024-04-01 false false false 17 November 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Kamran Sarwar Rukhsana Hanif Amir Sarwar 07090581 2024-04-01 2025-03-31 07090581 2025-03-31 07090581 2024-03-31 07090581 core:NetGoodwill 2025-03-31 07090581 core:NetGoodwill 2024-03-31 07090581 core:LeaseholdImprovements 2025-03-31 07090581 core:PlantMachinery 2025-03-31 07090581 core:ComputerEquipment 2025-03-31 07090581 core:LeaseholdImprovements 2024-03-31 07090581 core:PlantMachinery 2024-03-31 07090581 core:ComputerEquipment 2024-03-31 07090581 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07090581 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 07090581 core:ShareCapital 2025-03-31 07090581 core:ShareCapital 2024-03-31 07090581 core:RetainedEarningsAccumulatedLosses 2025-03-31 07090581 core:RetainedEarningsAccumulatedLosses 2024-03-31 07090581 bus:Director1 2024-04-01 2025-03-31 07090581 core:Goodwill 2024-04-01 2025-03-31 07090581 core:LeaseholdImprovements 2024-04-01 2025-03-31 07090581 core:PlantMachinery 2024-04-01 2025-03-31 07090581 core:ComputerEquipment 2024-04-01 2025-03-31 07090581 2023-04-01 2024-03-31 07090581 core:NetGoodwill 2024-03-31 07090581 core:NetGoodwill 2024-04-01 2025-03-31 07090581 core:LeaseholdImprovements 2024-03-31 07090581 core:PlantMachinery 2024-03-31 07090581 core:ComputerEquipment 2024-03-31 07090581 2024-03-31 07090581 core:CurrentFinancialInstruments 2025-03-31 07090581 core:CurrentFinancialInstruments 2024-03-31 07090581 core:WithinOneYear 2025-03-31 07090581 core:WithinOneYear 2024-03-31 07090581 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07090581 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 07090581 bus:FRS102 2024-04-01 2025-03-31 07090581 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 07090581 bus:Director2 2024-04-01 2025-03-31 07090581 bus:Director3 2024-04-01 2025-03-31 07090581 bus:FullAccounts 2024-04-01 2025-03-31 xbrli:pure xbrli:shares iso4217:GBP